Haw Par Valuation

Q: What is the Fair Price of H02 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

H02 (SGD11.17) is trading above our estimate of [[fair value]] (SGD9.52)

Is H02 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of H02 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: H02 (SGD11.17) is trading above our estimate of fair value (SGD9.52)

Significantly Below Fair Value: H02 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for H02?

Key metric: As H02 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for H02. This is calculated by dividing H02's market cap by their current earnings.
What is H02's PE Ratio?
PE Ratio	10.5x
Earnings	S$234.43m
Market Cap	S$2.47b

H02 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.5x
Enterprise Value/EBITDA	27.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does H02's PE Ratio compare to its peers?

The above table shows the PE ratio for H02 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.2x
1J5 Hyphens Pharma International	8.8x	6.7%	S$91.1m
HRMY Harmony Biosciences Holdings	15.8x	32.8%	US$1.9b
300705 Hunan Jiudian Pharmaceutical	22.6x	25.5%	CN¥11.5b
ERIS Eris Lifesciences	53.7x	30.7%	₹187.0b
H02 Haw Par	10.5x	n/a	S$2.5b

Price-To-Earnings vs Peers: H02 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the peer average (25.1x).

Price to Earnings Ratio vs Industry

How does H02's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 Companies	Price / Earnings	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: H02 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the Asian Pharmaceuticals industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is H02's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

H02 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate H02's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.